Richard Wooster
Richard Wooster is an Executive Partner of Syncona Investment Management Ltd.
Dr. Wooster is Chief Scientific Officer and a Director of Slingshot Therapeutics. Dr. Wooster brings extensive experience of creating drug discovery strategies and leading discovery teams at pharmaceutical and biotechnology companies. He most recently served as the Chief Scientific Officer at Translate Bio, which was acquired by Sanofi in September 2021. Dr. Wooster joined Translate Bio from Tarveda Therapeutics where he was Chief Scientific Officer and President of R&D. In addition to advancing multiple programs from early-stage discovery into the clinic, Dr. Wooster helped the company raise multiple rounds of private funding to advance the business. Prior to Tarveda, he was Vice President and Discovery Performance Unit Head in Oncology at GlaxoSmithKline.
Dr. Wooster began his career in academia at the Institute of Cancer Research where he discovered the BRCA2 gene and as a founder of the Cancer Genome Project at the Wellcome Trust Sanger Institute where mutations in BRAF were first discovered. He received his PhD from the University of Dundee and has co-authored over 100 publications, book chapters, and patents.
Syncona portfolio companies
- Slingshot Therapeutics (Director & CSO)
